SABCS: Active Monitoring Noninferior to Guideline Care for Ductal Carcinoma in Situ

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 13, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 13, 2024 -- For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) that involves surgery with or without adjuvant radiation, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.

E. Shelley Hwang, M.D., M.P.H., from the Duke University School of Medicine in Durham, North Carolina, and colleagues examined the outcomes of 995 participants with grade 1 or 2 hormone receptor-positive, human epidermal growth factor receptor 2-negative DCIS enrolled in the Comparing an Operation to Monitoring, with or without Endocrine Therapy for low risk DCIS trial who were randomly assigned to GCC (473 patients) or AM (484 patients). Participants in the AM group underwent surgical intervention only upon invasive progression diagnosis, or they could elect to have surgery at any time. Patients were allowed to receive endocrine therapy if desired, in both treatment arms.

The researchers found that 27 patients in the GCC arm and 19 in the AM arm had been diagnosed with invasive ipsilateral breast cancer after 24 months of follow-up. The two-year cumulative rate of invasive ipsilateral breast cancer was 5.9 and 4.2 percent for the GCC and AM arms, respectively, meeting the threshold for noninferiority. More patients in the AM versus GCC arm received endocrine therapy (71.3 versus 65.5 percent). Of those receiving endocrine therapy, invasive ipsilateral cancer was seen in 7.15 percent of patients in the GCC arm and 3.21 percent in the AM arm.

"Omission of surgery has been highly controversial, with both patients and providers fearing that it might result in an unacceptably high rate of patients who develop invasive cancer," Hwang said in a statement. "Our findings are reassuring, and longer-term follow up will have important implications for the future inclusion of active monitoring as a treatment option for low-risk DCIS."

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-12-14 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords